SASKATOON, Saskatchewan – (BUSINESS WIRE) – November 17, 2021–
ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company at the forefront of scientific research and development in herbal medicine, today announced the launch of a new formulation of drug-dominant medical cannabinoids in THC, Zylem â¢ 20: 1, for direct sale and distribution to registered medical patients across Canada. The launch of this formulation marks an important milestone in ZYUS ‘mission to elevate cannabinoids as the standard of care and harness their transformative potential.
ZYUS refines its cannabinoid extracts in an industry-leading pharmaceutical grade extraction facility using only raw materials sourced from licensed producers regulated by Health Canada. ZYUS ethanol based technology is used to achieve superior extraction efficiency while ensuring high product quality and long shelf life. ZYUS is committed to providing the highest quality, with all products subjected to rigorous testing from production to distribution, to ensure consistent and standardized formulations that patients and healthcare professionals can rely on.
âAt ZYUS, we are committed to providing patients with high-quality formulations for compassionate care, supported by our team’s decades-long leadership in the medical cannabinoid field,â said ZYUS CEO Brent Zettl. âWith millions of Canadians suffering, we are proud to offer patients another new formulation of cannabinoids to help them manage their disease and associated symptoms. “
Further expanding the existing ZYUS medical product offering of cannabinoid extracts and topical cannabinoid formulations, this new THC-dominant extract formulation (Zylem â¢ 20: 1), is available for direct sale and distribution to patients. registered medical professionals across Canada. Prospective patients or healthcare professionals seeking more information about ZYUS or its products can visit ZYUS.ca or speak to a member of the ZYUS patient care team at 1-833-713-CARE (2273).
About ZYUS Life Sciences Inc.
ZYUS is a Canadian life sciences company focused on the development and global commercialization of innovative cannabinoid therapeutics and product candidates. Through clinical research and intellectual property development, we intend to provide high quality oils, capsules, topical creams and other therapeutic products and cannabinoid product candidates to patients around the world. whole. ZYUS’s vision is to elevate cannabinoids as the standard of care and to expand the potential of protein-based formulations in the pursuit of transformational impact on the lives of patients. ZYUS: Advancing the science of wellness. Visit www.zyus.com.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause ZYUS ‘actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by the statements. prospective. These forward-looking statements include, without limitation, expectations regarding our business plans, research activities, product lines, efficiency and patient services.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects”, “,”,, “continuing”, “potential”, “targeted”, “plans”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could”, “could” or “” should “occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions, including that all necessary approvals and permits will be obtained and assumptions regarding ZYUS ‘ability to continue to ensure product consistency and quality through sourcing, manufacturing processes. and robust testing, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company, and cannot be predicted or quantified and, therefore, actual results may differ materially from those expressed or under – understood by these forward-looking statements. These risks include the risk that ZYUS may not be able to continue to ensure product consistency and quality through robust sourcing, manufacturing and testing processes.
Therefore, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Because forward-looking statements and information deal with future events and conditions, by their very nature they involve inherent risks and uncertainties.
Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements contained in this press release are made as of the date of this press release and, therefore, are subject to change after such date. ZYUS assumes no obligation to update or revise any forward-looking statements or information, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20211117005342/en/
CONTACT: ZYUS Media inquiries
1-833-515-5500ZYUS Investor Relations
Bruce M. Mann
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORDS: ALTERNATIVE MEDICINE HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE
SOURCE: ZYUS Life Sciences Inc.
Copyright Business Wire 2021.
PUB: 11/17/2021 07:35 / DISC: 11/17/2021 07:36
Copyright Business Wire 2021.